Treatment Advances in Atopic Dermatitis Care: Updates for the Specialty Pharmacist

Treatment Advances in Atopic Dermatitis Care: Updates for the Specialty Pharmacist

On-Demand 1.5-hour Accredited Webcast

Faculty Presenters

Jamie L. McConaha, PharmD, NCTTP, BCACP, CDCES
Associate Professor of Pharmacy Practice
Duquesne University School of Pharmacy
Pittsburgh, Pennsylvania

Megan Schneider, PharmD
Clinical Pharmacist
Vanderbilt University Medical Center Specialty Pharmacy
Nashville, Tennessee
 
Program Description
Though atopic dermatitis (AD) has historically been considered a childhood disease, estimates suggest up to more than 1.5 million adults in the United States live with moderate to severe AD. When AD is inadequately controlled, it can result in unnecessary and significant clinical and economic burden for patients, and it can especially impact patient quality of life. Further investigation into the inflammatory pathways that trigger AD has contributed to expanding treatment options, such as those targeting the Janus kinase and interleukin pathways, which are now known to be implicated in AD. Several small molecules and biologics are in development and offer new options and different modes of administration for patients who have AD. Specialty pharmacists should be familiar with existing treatment guidelines and how new therapies may affect the current treatment landscape. This activity will review current therapies with a focus on emerging agents for moderate to severe AD and equip specialty pharmacists to apply safe and effective targeted therapies to treatment plans to improve care for patients with AD.

Target Audience: Managed care and specialty pharmacists
Type of Activity: Application
Release date: June 3, 2021
Expiration date: June 3, 2022
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Document the pathophysiology of atopic dermatitis and the relevance of newly discovered targets for current and new therapeutic agents
• Examine the mechanism of action and clinical trial results including efficacy and safety data for FDA-approved and investigational atopic dermatitis treatments
• Identify situations in which referral to a specialist is needed and patients who may benefit from new therapies in their treatment plans

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-221-H01-P. The activity is available for CE credit through June 3, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Jamie L. McConaha, PharmD, NCTTP, BCACP, CDCES, and Megan Schneider, PharmD, have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Rose Namissa, PharmD, BCPS; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms